Mylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma - MarketWatch

Mylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma - MarketWatch | marketing - Google News | April 10, 2018 at 09:15AM

Mylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma MarketWatch Mylan N.V. MYL, +3.89% said Tuesday it has agreed to acquire the global marketing rights to a once-monthly treatment for multiple sclerosis from Israel's Mapi Pharma. Mylan is acquiring GA Depot, a long-acting Glatiramer Acetate product that is used to ...

April 10, 2018 at 09:15AM | marketing - Google News
Mylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma - MarketWatch
marketing - Google News